|Articles|August 1, 2003

Examining the Dyslipidemia Constellation
Volume 9
Issue 1 Dyslipid

NCEP ATP III guidelines incorporate global risk assessment

Author(s)Antionio M. Gotto, DPhil

Download PDF: NCEP ATP III guidelines incorporate global risk assessment

Articles in this issue

about 23 years ago

Article

Case reports illustrate consequences of ATP III in practice

about 23 years ago

Article

Interview: Intergrating clinical trial results into managed care practice

about 23 years ago

Article

Inflammatory markers are useful risk assessment tools

about 23 years ago

Article

Atherosclerosis target of lipid-lowering therapy: Is Lower LDL cholesterol better?

about 23 years ago

Article

IVUS is redefining atherosclerotic disease

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

NCEP ATP III guidelines incorporate global risk assessment

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care

GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis

ICER Draft Flags High Cost of New Hypertension Drug Class

Medicare Accountable Care Organizations: Clinical Performance for Patients With Heart Failure